Pharmacology is the cornerstone of clinical practice. For the physician assistant (PA) and nurse practitioner (NP), staying current on pharmacokinetics, drug-drug interactions, and emerging therapeutic classes is not just a regulatory requirement; it is a clinical necessity. Whether you are preparing for the PANRE or fulfilling annual state-mandated credit hours, pharmacology-specific CME ensures you maintain safe prescribing habits in an increasingly complex medical landscape.
Course Logistics and Deliverables
- Course Titles: 20-Hour Pharmacology Course and PANRE Review Course
- AAPA Category 1 Credit: 20 hours (Pharmacology Course) / 100 hours (PANRE Review Course)
- Price: $449.99 (Pharmacology) / $399.99 (PANRE Review)
- Duration of Access: 30 Months
- Deliverables: Comprehensive video lectures and high-yield board-style review questions (1,672 questions in the PANRE Review)
- Gift Card Add-ons: Available from $100 to $1,500 (Amazon or Apple)
The Critical Need for Specialized Pharmacology CME
Maintaining licensure requires a specific focus on pharmacology, particularly as state boards increase oversight on controlled substances and medication safety. For PAs, obtaining AAPA Category 1 Credit is the gold standard for satisfying NCCPA requirements. While general clinical credits are valuable, dedicated pharmacology hours provide a deeper dive into the mechanisms that drive patient outcomes.
Nurse Practitioners also find significant value in these courses. While AAPA Category 1 credit is primarily designed for PAs, many state nursing boards and the AANP recognize these hours toward the mandatory pharmacology requirements for NP recertification. It is essential to check your specific state board regulations, but the clinical depth of these courses: written by PAs for PAs: translates directly to the high-acuity needs of NP practice.
20-Hour Pharmacology Course vs. 100-Hour PANRE Review
Choosing the right course depends on your current certification cycle and educational needs.
The 20-Hour Pharmacology Course is an efficient, targeted program designed for clinicians who need to satisfy pharmacology-specific mandates without the overhead of a full board review. It focuses on the high-yield medications found in Emergency Medicine, Internal Medicine, and Family Medicine.
The PANRE Review Course offers a more comprehensive approach, delivering 100 hours of AAPA Category 1 credit. This course is specifically structured to follow the NCCPA Blueprint, ensuring that every hour spent studying directly contributes to passing the recertification exam. While it covers the full spectrum of clinical medicine, the pharmacology integrated into this 100-hour package is designed to mirror the difficulty and style of the actual board questions.
The Advantage of CME with Gift Card Add-ons
Maximizing your CME budget is a practical concern for every medical professional. CME Review Courses provides an efficient way to utilize your employer-provided CME funds. By choosing a package with an Amazon or Apple Gift Card add-on, you can secure the necessary educational credits while also obtaining a gift card ranging from $100 to $1,500. This allows you to purchase additional educational tools, medical equipment, or technology required for your practice.
These packages are designed to be an efficient use of your professional development allowance. The cost of the gift card is included in the total package price, providing a streamlined way to manage your educational expenses for the year.
Clinical Scenario: Cardiovascular Pharmacology
Your patient is a 64-year-old male with a history of HTN and HFrEF (EF 35%) who presents for a follow-up. He was recently started on an ACE inhibitor and a beta-blocker. His current BP is 138/84 mmHg and HR is 62 bpm. He complains of a persistent, dry, non-productive cough that began shortly after starting his new medications.
Which of the following is the most appropriate next step in the pharmacological management of this patient’s hypertension and heart failure?
A. Discontinue the beta-blocker and start a Calcium Channel Blocker
B. Discontinue the ACE inhibitor and start an ARB (Angiotensin II Receptor Blocker)
C. Add an inhaled corticosteroid to treat the cough
D. Decrease the dose of the ACE inhibitor by half
Correct Answer: B. Discontinue the ACE inhibitor and start an ARB.
Explanation: The patient is experiencing a classic side effect of ACE inhibitors: a bradykinin-induced dry cough. This occurs in up to 20% of patients. Since the patient has HFrEF, maintaining inhibition of the RAAS system is mandatory for mortality benefit. Switching to an ARB provides similar clinical outcomes without the accumulation of bradykinin, thus resolving the cough while maintaining the necessary heart failure management. Beta-blockers are not associated with this type of cough, and adding a corticosteroid or lowering the dose would not address the underlying mechanism of the adverse effect.
Clinical Scenario: Endocrine Pharmacology
Your patient is a 52-year-old female with Type 2 Diabetes Mellitus, currently managed with Metformin 1000mg BID. Her A1c remains elevated at 8.2%. She has a BMI of 34 kg/m² and a history of atherosclerotic cardiovascular disease (ASCVD). You decide to add a second-line agent.
According to current guidelines, which class of medication is the most appropriate addition for this patient?
A. Sulfonylureas
B. DPP-4 inhibitors
C. GLP-1 Receptor Agonists
D. TZDs (Thiazolidinediones)
Correct Answer: C. GLP-1 Receptor Agonists.
Explanation: For patients with Type 2 Diabetes and established ASCVD, GLP-1 receptor agonists (such as liraglutide or semaglutide) or SGLT2 inhibitors are recommended as second-line therapy after metformin. These classes have demonstrated significant cardiovascular mortality benefits. Additionally, GLP-1 agonists assist with weight loss, which is beneficial given the patient's BMI. Sulfonylureas and TZDs do not provide the same cardiovascular protection and may cause weight gain.
Clinical Scenario: Neurology Pharmacology
Your patient is a 28-year-old female presenting with a 2-day history of "worst headache of my life" that was sudden in onset. CT head is negative for subarachnoid hemorrhage, but a follow-up lumbar puncture shows xanthochromia. The diagnosis of SAH is confirmed.
Which medication should be initiated to reduce the risk of ischemic complications due to vasospasm in this patient?
A. Nimodipine
B. Lisinopril
C. Phenytoin
D. Mannitol
Correct Answer: A. Nimodipine.
Explanation: Nimodipine, a dihydropyridine calcium channel blocker, is specifically indicated in the management of subarachnoid hemorrhage to improve neurological outcomes by reducing the incidence and severity of ischemic deficits caused by cerebral vasospasm. It should be started within 96 hours of the hemorrhage. Lisinopril is used for chronic hypertension but not acute vasospasm. Phenytoin may be used for seizure prophylaxis but does not prevent vasospasm. Mannitol is used to reduce intracranial pressure but is not the primary agent for vasospasm prevention.
Clinical Scenario: Infectious Disease Pharmacology
Your patient is a 24-year-old male presenting with a purulent, fluctuant abscess on his left thigh. He has no systemic symptoms (no fever, HR 78, BP 120/80). You perform an incision and drainage (I&D). You decide to provide empiric antibiotic coverage for MRSA.
Which of the following oral antibiotics provides appropriate coverage for community-acquired MRSA in this patient?
A. Cephalexin
B. Trimethoprim-Sulfamethoxazole (TMP-SMX)
C. Amoxicillin-Clavulanate
D. Azithromycin
Correct Answer: B. Trimethoprim-Sulfamethoxazole (TMP-SMX).
Explanation: TMP-SMX is a first-line oral option for the treatment of community-acquired MRSA skin and soft tissue infections. Cephalexin and Amoxicillin-Clavulanate (Augmentin) provide excellent coverage for MSSA and Streptococcus but are ineffective against MRSA. Azithromycin has high rates of resistance among Staphylococcal species and is not recommended for purulent skin infections.
Educational Value and Career Advancement
Investing in high-quality pharmacology CME is an investment in your clinical autonomy. As the pharmaceutical industry introduces new biologics and targeted therapies, the gap between standard training and current practice widens. The 20-Hour Pharmacology Course and the 100-Hour PANRE Review from CME Review Courses bridge this gap, providing the authoritative knowledge required to practice at the top of your license.
By utilizing the Amazon or Apple Gift Card add-on options, you efficiently manage your professional resources while securing the highest quality AAPA Category 1 credits available. Whether you are a PA, NP, or physician looking for Category 2 value, these programs deliver the concise, board-style information needed to succeed in modern clinical practice.
For more information on these courses and to view our full catalog, visit cmereviewcourses.com.